BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 24608297)

  • 1. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
    Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
    Blazy A; Hennequin C; Gornet JM; Furco A; Gérard L; Lémann M; Maylin C
    Dis Colon Rectum; 2005 Jun; 48(6):1176-81. PubMed ID: 15906137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
    Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
    Wexler A; Berson AM; Goldstone SE; Waltzman R; Penzer J; Maisonet OG; McDermott B; Rescigno J
    Dis Colon Rectum; 2008 Jan; 51(1):73-81. PubMed ID: 18066626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
    Hauerstock D; Ennis RD; Grossbard M; Evans A
    Clin Colorectal Cancer; 2010 Oct; 9(4):238-42. PubMed ID: 20920996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era.
    Grew D; Bitterman D; Leichman CG; Leichman L; Sanfilippo N; Moore HG; Du K
    Dis Colon Rectum; 2015 Dec; 58(12):1130-6. PubMed ID: 26544809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.
    Cunin L; Alfa-Wali M; Turner J; Bower M; Ion L; Allen-Mersh T
    Ann Surg Oncol; 2014 Feb; 21(2):527-32. PubMed ID: 24242676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance of pretreatment leukocytosis in patients with anal cancer treated with radical chemoradiotherapy or radiotherapy.
    Banerjee R; Roxin G; Eliasziw M; Joseph K; Maclean A; Buie WD; Doll C
    Dis Colon Rectum; 2013 Sep; 56(9):1036-42. PubMed ID: 23929012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
    White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
    Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
    Doyen J; Benezery K; Follana P; Ortholan C; Gérard JP; Hannoun-Levi JM; Gal J; Francois E
    Dis Colon Rectum; 2013 Oct; 56(10):1125-33. PubMed ID: 24022529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.
    Edelman S; Johnstone PA
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):206-11. PubMed ID: 16904522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
    Chen YW; Yen SH; Chen SY; Huang PI; Shiau CY; Liu YM; Lin JK; Wang LW
    J Surg Oncol; 2007 Oct; 96(5):374-80. PubMed ID: 17492635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
    Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
    Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?
    Fraunholz I; Rabeneck D; Gerstein J; Jäck K; Haberl A; Weiss C; Rödel C
    Radiother Oncol; 2011 Jan; 98(1):99-104. PubMed ID: 21168927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy.
    Oehler-Jänne C; Huguet F; Provencher S; Seifert B; Negretti L; Riener MO; Bonet M; Allal AS; Ciernik IF
    J Clin Oncol; 2008 May; 26(15):2550-7. PubMed ID: 18427149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.